Ghent, Belgium – Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO) enabling precision medicines and complex therapies, has announced the appointment of Ariane de Ganck, PhD, as Chief Scientific Officer. This strategic move underscores Ardena’s commitment to scientific excellence across its integrated service offering, supporting clients from early development through late-stage clinical and commercial supply.
Role and Responsibilities
As Chief Scientific Officer, Dr. de Ganck will lead three key areas: Science & Technology, Project Management, and CMC Regulatory Affairs. Through Science & Technology, she will foster scientific exchange within Ardena and with external industry experts and thought leaders, ensuring that scientific knowledge and expertise are effectively shared across disciplines and sites. She will also oversee Project Management across all Ardena locations, promoting a consistent, science-driven, and high-quality customer experience. Additionally, she will continue to lead Ardena’s CMC Regulatory Affairs, helping clients navigate complex development pathways with regulatory strategies that support clinical and commercial approvals globally across any modality.
Proven Track Record
Ariane brings a strong track record within Ardena, including her leadership of the company’s Drug Product division since 2022 and her recent role as Chief Commercial Officer. Since joining Ardena in 2019, she has overseen drug product operations, led the successful acquisition and integration of the Ardena Pamplona site, and supported the expansion of Ardena’s development capabilities into aseptic fill and finish services. Her senior management experience spans the CRO and CDMO sectors, with expertise in drug product development, CMC regulatory affairs, biomarkers, and laboratory services.
Leadership Perspective
“Ariane’s track record across scientific, operational, and commercial leadership roles makes her exceptionally well suited to this position,” said Jeremie Trochu, CEO of Ardena. “For customers developing complex molecules, integrated scientific input across disciplines is essential. As Chief Scientific Officer, Ariane will help ensure Ardena’s expertise is applied consistently across complex development programs, supporting our customers as they advance therapies with the potential to improve patients’ lives.”
Background
Prior to joining Ardena, Dr. de Ganck worked at Biogazelle, a specialist CRO in biomarker discovery and diagnostics, until its successful sale to CellCarta. She is recognized for leading multidisciplinary teams, developing people, building strong internal and external networks, and maintaining a customer-centric approach. She holds a PhD in Biomedical Sciences with a specialty in oncology and protein biology. Her research focused on understanding proteins driving cancer cell migration and invasion. She subsequently advanced into nanobody research, working with camelid single-domain antibodies to target cancer-related proteins, an approach that underpins next-generation biotherapeutics and aligns closely with Ardena’s capabilities in complex drug development.
This appointment reflects Ardena’s continued focus on scientific excellence across its integrated offering, ensuring that complex drug development programs benefit from coordinated technical insight, consistent project execution, and robust regulatory strategy.
